3 January 2024 in Clinical Pharmacology & Therapeutics
16 June 2022 in Clinical Pharmacology & Therapeutics
16 October 2021 in Clinical Pharmacology & Therapeutics
31 May 2016 in Clinical Cancer Research
Evaluation of dose plays a critical role in a successful oncology development program. Typically for oncology agents, the first-in-man phase I dose-escalation trials are conducted to determine a maximum tolerated dose (MTD). This MTD is taken forward into subsequent trials to establish the safety and efficacy of the drug product. Although this approach was appropriate historically for cytotoxics, the application of MTD as the recommend phase II dose has been problematic for the newer small molecule–targeted oncology agents. Promising alternative approaches using dose and exposure exploration, including lessons learned from recent targeted oncology agent development and approvals, are summarized and discussed. Clin Cancer Res; 22(11); 2630–8. ©2016 AACR.
12 December 2023 in Clinical Pharmacology & Therapeutics
Artificial intelligence (AI) is increasingly being used in decision making across various industries, including the public health arena. Bias in any decision‐making process can significantly skew outcomes, and AI systems have been shown to exhibit biases at times. The potential for AI systems to perpetuate and even amplify biases is a growing concern. Bias, as used in this paper, refers to the tendency toward a particular characteristic or behavior, and thus, a biased AI system is one that shows biased associations entities. In this literature review, we examine the current state of research on AI bias, including its sources, as well as the methods for measuring, benchmarking, and mitigating it. We also examine the biases and methods of mitigation specifically relevant to the healthcare field and offer a perspective on bias measurement and mitigation in regulatory science decision making.
11 January 2020 in Clinical Pharmacology & Therapeutics